Statistics from Altmetric.com
Tumour necrosis factor α (TNF-α) plays a pivotal role in the pathogenesis of Crohn’s disease. Infliximab, a chimeric monoclonal antibody against TNF-α, has been shown to be highly effective in the treatment of Crohn’s disease.1 However, treatment with infliximab may give rise to serious adverse events, including autoimmune disorders.2 We report a case of fatal aseptic meningitis associated with infliximab therapy.
A 53 year old Caucasian man was admitted to a regional hospital with progressive bloody diarrhoea. His medical history revealed a myocardial infarction in 1993. Endoscopy and histology established a diagnosis inflammatory bowel disease (IBD) but could not distinguish between ulcerative colitis and Crohn’s disease. Because his symptoms did not improve following steroid and azathioprine treatment, infliximab therapy was initiated. Six days after the initial infliximab infusion, temporary numbness of …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.